BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BofA lowered its price target for Krystal Biotech, citing growth concerns in August 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America is lowering earnings estimates for AutoNation using data from Kelley Blue Book analysis.
- Jefferies Financial Group and Bank of America lowered price targets for Constellation Brands on June 29, 2026.
- Bank of America analysts visited Walmart and Target stores in Nashville to observe corporate strategies.
- Bank of America analysts raised price targets for several U.S. industrial and healthcare stocks in July 2025.
- Bank of America reported underperformance in earnings and failed to report suspicious transactions.
Coverage
Newest first; wire copies grouped- TipRanksKrystal Biotech price target lowered to $182 from $192 at BofA BofA analyst Alec Stranahan lowered the firm’s price target on Krystal Biotech (KRYS) to $182 from $192 and keeps a Buy rating on the sh